[新生血管膜与妊娠。贝伐单抗治疗]
[Neovascular membrane and pregnancy. Treatment with bevacizumab].
作者信息
Gómez Ledesma I, de Santiago Rodríguez M Á, Follana Neira I, León Garrigosa F
机构信息
Servicio de Oftalmología, Hospital Universitario Virgen de la Vega, Salamanca, España.
出版信息
Arch Soc Esp Oftalmol. 2012 Sep;87(9):297-300. doi: 10.1016/j.oftal.2011.09.011. Epub 2012 May 30.
CLINICAL CASE
Female in her sixth month of pregnancy, with a history of refractive surgery, who consulted due to a metamorphopsia and decrease in visual acuity in the right eye. A presumed ocular histoplasmosis syndrome (POHS) and a subfoveal choroidal neovascular membrane were observed in the fundoscopy. Two monthly doses of intravitreal bevacizumab were given after the labour, but the third dose was never inyected as the patient became pregnant again. She subsequently had a spontaneous miscarriage.
DISCUSSION
Treatment with intravitreal bevacizumab during pregnancy is controversial as it may increase the risk of miscarriage during the first trimester.
临床病例
一名怀孕6个月的女性，有屈光手术史，因右眼出现视物变形和视力下降前来就诊。眼底检查发现疑似眼组织胞浆菌病综合征（POHS）和黄斑下脉络膜新生血管膜。产后给予每月两次玻璃体内注射贝伐单抗，但由于患者再次怀孕，第三剂未注射。随后她发生了自然流产。
讨论
孕期使用玻璃体内注射贝伐单抗进行治疗存在争议，因为它可能会增加孕早期流产的风险。
Zotero 插件